A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/23/2019
Start Date:May 11, 2016
End Date:February 28, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to
participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will
evaluate how the body processes the drug and how the drug affects the body. The study will
also evaluate the association between tumor response and the participant's perceived quality
of life.


Inclusion Criteria:

- Have ED-SCLC and have received a prior platinum-based regimen

- Participants in Cohort 1 and in the addendum must have had an objective response to
prior platinum-based therapy with subsequent progression ≥90 days after the last dose
of platinum

- Participants in Cohort 2 must have either not had an objective response to prior
platinum based therapy or had progression <90 days after the last dose of platinum

- Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale

Exclusion Criteria:

- Have received more than 2 prior therapies for ED-SCLC (including immunotherapy,
targeted therapies, or chemotherapy)

- Have symptomatic central nervous system (CNS) malignancy or metastasis. Asymptomatic
participants with treated CNS metastases are eligible for this study if they are not
currently receiving corticosteroids to treat CNS metastases

- Have previously completed or withdrawn from this study or any other study
investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor or have shown
hypersensitivity to any of the components of the prexasertib formulation

- Have a serious cardiac condition
We found this trial at
15
sites
The Center for Cancer and Blood Disorders
Fort Worth, Texas 76104
Principal Investigator: Ray Page
Phone: 817-759-7023
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Florida Cancer Specialists
3840 Broadway
Fort Myers, Florida 33901
(239) 275-6400
Principal Investigator: Michael McCleod
Phone: 239-274-9930
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Vanderbilt University Medical Center
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Leora Horn
Phone: 615-322-4967
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Clinical Trial Facility in Besancon Cedex
Besancon Cedex, 25030
?
mi
from
Besancon Cedex,
Click here to add this to my saved trials
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee 37404
Principal Investigator: Davey Daniel
Phone: 423-698-1844
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Massachusetts General Hospital
Danvers, Massachusetts 01923
?
mi
from
Danvers, MA
Click here to add this to my saved trials
Highlands Oncology Group, P.A.
Fayetteville, Arkansas 72703
Principal Investigator: Eric Schaefer
Phone: 479-587-1700
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Principal Investigator: Lauren Byers
Phone: 713-792-2848
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Dartmouth Hitchcock Medical Center
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Konstantin Dragnev
Phone: 603-650-6344
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Sarah Cannon Cancer Center
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Principal Investigator: SMO Sarah Cannon Research Inst
Phone: 615-329-7274
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Tennessee Oncology, PLLC
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Melissa Johnson
Phone: 615-329-7274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Yale University School of Medicine
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: Anne Chiang
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Washington University Medical Center
Saint Louis, Missouri 63110
Principal Investigator: Saiama Waqar
Phone: 314-362-5817
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Florida Cancer Specialists and Research Institute
Saint Petersburg, Florida 33705
Principal Investigator: Maen Hussein
Phone: 72721611433081
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Georgetown University Medical Center
3800 Reservoir Rd NW
Washington, District of Columbia 20007
(202) 687-7695
Principal Investigator: Deepa Subramaniam
Phone: 202-444-2144
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
?
mi
from
Washington,
Click here to add this to my saved trials